Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(14%)

Phase Distribution

Ph not_applicable

43%

Ph phase_1

14%

Ph phase_2

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

1(14.3%)

Phase 2Efficacy & side effects

3(42.9%)

N/ANon-phased studies

3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Other(2)

Detailed Status

Completed4

Terminated1

Suspended1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (14.3%)

Phase 23 (42.9%)

N/A3 (42.9%)

Trials by Status

terminated114%

completed457%

suspended114%

unknown114%

Recent Activity

0 active trials

Showing 5 of 7

completedphase_1

A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)

NCT00001006

suspendedphase_2

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

NCT01010373

terminatedphase_2

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

NCT00926354

unknownphase_2

Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

NCT00418249

completednot_applicable

A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease

NCT00002033

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT00001006Phase 1

A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)

Completed

NCT01010373Phase 2

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Suspended

NCT00926354Phase 2

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Terminated

NCT00418249Phase 2

Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Unknown

NCT00002033Not Applicable

A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease

Completed

NCT00002013Not Applicable

A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients

Completed

NCT00002266Not Applicable

An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7